Coherus Oncology, Inc.
CHRS · XNASCIK 1512762fmd_1AKC87E1HWGQ2SPEEACG7D60BBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 190 | 2 | 0 | 356 | 476 | 327 | 211 | 1 | 26 | 42 |
| Cost of revenue | – | – | – | 17 | 38 | 58 | 70 | 0 | 9 | 14 |
| Gross profit | – | – | – | 339 | 438 | 269 | 141 | 1 | 18 | 28 |
| Research and development | 254 | 162 | 110 | 94 | 143 | 363 | 199 | 96 | 92 | 109 |
| Selling, general and administrative | 52 | 71 | 94 | 137 | 139 | 170 | 198 | 120 | 125 | 101 |
| Total operating expenses | 306 | 234 | 204 | 248 | – | – | – | – | – | – |
| Operating income | (116) | (232) | (204) | 108 | 156 | (264) | (257) | (216) | (200) | (181) |
| Interest expense | 8 | 10 | 10 | 18 | 21 | 23 | 32 | 11 | 11 | 9 |
| Interest and investment income | – | – | 1 | 2 | 1 | 1 | 2 | 3 | 5 | 7 |
| Other non-operating income (expense) | (4) | 3 | 5 | 3 | 1 | (0) | 4 | 5 | 8 | 7 |
| Income before taxes | – | (238) | (209) | 93 | 136 | (287) | (292) | (222) | (215) | (183) |
| Income tax expense | 0 | 0 | 0 | 3 | 3 | 0 | 0 | (0) | 0 | 0 |
| Net income from continuing operations | – | (238) | (209) | 90 | 132 | (287) | (292) | (222) | (215) | (183) |
| Net income | (127) | (238) | (209) | 90 | 132 | (287) | (292) | (238) | 29 | 168 |